Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39feae37f316991ed5248a15d5a15747 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
filingDate |
2007-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2011-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d01fd1b2acf185c72497f6acefbc1dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ebf7bae2f075911a5ecb5ed302d1ca2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e58e785500e8a5f0cf0b81281b0510a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efeef250a2c4f88d19ac162905e54bf9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_503276f6af54aa8a0c2dc3371f710cf7 |
publicationDate |
2011-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2089425-B1 |
titleOfInvention |
Anti-angiogenic compounds |
abstract |
The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis. |
priorityDate |
2006-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |